Dow Corning Corporation

Escalon Medical Corporation

David Clayton Gantner

Victor Albert Raul

Eric Jude Joffre

Katherine L Ulman

Xavier Thomas

Csilla Kollar

Xavier Jean-Paul Thomas

Gerald Kenneth Schalau, Ii

Joseph Charles McAuliffe

Alan L Weiner

Bartley Dean Maxon

Gary Lee Loubert

Sohrab Darougar

Virginie Caprasse

Padmanabh Pravinchandra Bhatt

Keith Alan LaChance

Debra Jo Nagy Zellner

Joseph C Mcauliffe

Gerald Kenneth Ii Schalau

Katherine Ulman

The invention provides: a cross-linkable therapeutic composition comprising a) a saccharide-siloxane copolymer; b) a crosslinking agent; c) one or more active/inactive ingredients; and d) optionally, a solvent, or solvent mixture, wherein the saccharide-siloxane copolymer has the following formula: RaR(3-a)SiO&#x2014;[(SiRRO)m-(SiR2O)n]y-SiR(3-a)Ra that is further formulaically defined and wherein the saccharide-siloxane copolymer is a reaction product of a functionalized organosiloxane polymer and at least one hydroxy-functional saccharide such that the organosiloxane component is covalently linked via a linking group to the saccharide component; films; and methods related thereto. The composition has therapeutic properties. The invention also provides articles of manufacture including topical and transdermal agent delivery patches comprising the novel film-forming composition and/or films.

Silicone film former for delivery of actives

The invention provides a cross-linkable composition comprising a saccharide-siloxane copolymer according to a specified structural formula, a crosslinking agent, and, optionally, solvent. Cross-linked polymeric networks, cured coatings, and articles of manufacture formed from the inventive compositions are also provided, as well as processes and methods of manufacturing the inventive cross-linkable compositions and applications thereof.

Crosslinkable saccharide-siloxane compositions, and networks, coatings and articles formed therefrom

A method for increasing the adherence of a silicone gel to a substrate using a primer material. The method is particularly useful for adhering a medical prosthesis to a human or animal body.

Method for adhering silicone gels to plastics

A silicone adhesive composition used for adhering a device or a substance to a wet surface contains (i) a silicone resin that is cohydrolysis product of a trialkyl hydrolyzable silane and an alkyl silicate in which the cohydrolysis product contains a plurality of silicon-bonded hydroxy groups; (ii) a linear organopolysiloxane fluid containing terminal silicon-bonded hydroxy groups having a viscosity above 200,000 mm/at 25&#xb0; C.; (iii) a trialkylsiloxy terminated polyorganosiloxane fluid having a viscosity of 100,000-600,000 mm/at 25&#xb0; C.; (iv) a water soluble muco-adhesive polymer selected from the group consisting of a poly(ethylene oxide) polymer having a molecular weight of 100,000 to 8,000,000, an acrylic acid polymer having a molecular weight of 500,000 to 4,500,000,000, and a hydroxyethylcellulose polymer having a molecular weight of 90,000 to 1,300,000,000; and optionally, (v) a solvent selected from the group consisting of aliphatic hydrocarbons, aromatic hydrocarbons, esters, volatile linear and cyclic silicone compounds. Other components such as a silicone polyether, a silicone wax, a drug, an excipient, and/or an active ingredient can also be included.

Silicone adhesive for adhesion to wet surfaces

A formulation for depositing a film on a substrate comprising 5 to79.9 wt. % of an alkylene trialkoxy terminated polysiloxane; 0.01 to 5 wt. % of a catalyst; 20 to 94.99 to wt % of a volatile diluent, and, optionally, 0.01 to 5 wt. % of an alkoxysilane and 0.1 to 25 wt % of a filler. The formulations are especially valuable for forming films to be used in personal care or healthcare applications.

Fast cure film forming formulation

A flexible ocular insert device adapted for the controlled sustained release of an ophthalmic drug into the eye. In one embodiment, the device includes an elongated body of a polymeric material in the form of a rod or tube containing a pharmaceutically active ingredient and with at least two anchoring protrusions extending radially outwardly from the body. The device has a length of at least 8 mm and the diameter of its body portion including the protrusions does not exceed 1.9 mm. The sustained release mechanism may, for example, be by diffusion or by osmosis or bioerosion. The insert device is advantageously inserted into the upper or lower fornix of the eye so as to be independent of movement of the eye by virtue of the fornix anatomy. The protrusions may be of various shapes such as, for example, ribs, screw threads, dimples or bumps, truncated cone-shaped segments or winding braid segments. In a further embodiment, the polymeric material for the body is selected as one which swells in a liquid environment. Thus a device of smaller initial size may be employed. The present insert device is of a size and configuration such that, upon insertion into the upper or lower fornix, the device remains out of the field of vision so as to be well retained in place and imperceptible by a patient over a prolonged period of use. The device can be retained in the upper or lower fornix for 7 to 14 days or longer.

Ocular insert with anchoring protrusions

Growing community of inventors

Midland, MI, United States of America

David Clayton Gantner